Financial Performance - Net profit attributable to shareholders for the first nine months of 2024 was CNY -15,875,336.84, a decline of 129.77% compared to CNY -6,909,240.17 in the same period of 2023[3] - Operating revenue for the first nine months of 2024 decreased by 13.44% to CNY 86,106,323.16 from CNY 99,477,600.49 in the previous year[3] - The gross profit margin decreased significantly, leading to an operating loss of CNY -20,154,975.53, a decline of 71.89% compared to the previous year[5] - Operating profit for the first nine months of 2024 was -¥20,154,975.53, compared to -¥11,725,775.26 in the same period of 2023, indicating a worsening performance[27] - Net profit for the first nine months of 2024 was -¥15,875,336.84, compared to -¥6,909,240.17 in the same period of 2023, reflecting a significant increase in losses[27] - Total operating revenue for the first nine months of 2024 was ¥86,106,323.16, a decrease of 13.5% compared to ¥99,477,600.49 in the same period of 2023[26] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY -44,860,789.66, a significant decline of 99.01% compared to CNY -22,542,387.28 in the same period last year[3] - Operating cash inflow for the first nine months of 2024 was CNY 102,200,723.94, a decrease of 15.9% compared to CNY 121,614,958.73 in the same period of 2023[31] - Net cash outflow from operating activities was CNY -44,860,789.66, worsening from CNY -22,542,387.28 year-over-year[32] - Total cash outflow from investing activities was CNY 93,344,285.86, significantly higher than CNY 44,741,731.67 in the previous year[32] - Net cash flow from financing activities increased to CNY 31,653,383.58, compared to CNY 25,943,766.67 in the same period last year[32] Assets and Liabilities - Total assets as of September 30, 2024, amounted to CNY 497,634,890.51, representing a 2.87% increase from CNY 483,752,548.96 at the end of 2023[3] - Current liabilities rose to ¥177.88 billion, up from ¥146.89 billion, indicating an increase of about 21.1%[21] - Total liabilities increased to ¥224.53 billion from ¥194.77 billion, reflecting a growth of about 15.3%[22] - The total equity attributable to shareholders decreased to ¥278.77 billion from ¥289.85 billion, a decline of approximately 3.8%[25] Shareholder Information - The total number of ordinary shares at the end of the reporting period is 85,847,126, with 70.00% being unrestricted shares and 30.00% being restricted shares[8] - The largest shareholder, Wang Jie, holds 23,365,988 shares, representing 27.22% of the total shares[9] - The number of ordinary shareholders is 2,613 at the end of the reporting period[8] Research and Development - Research and development expenses increased by 51.05% to CNY 17,729,835.43, indicating a focus on ongoing projects despite a slight overall decrease in total R&D investment[4] - Research and development expenses rose to ¥17,729,835.43, an increase of 51.1% from ¥11,738,080.02 in the same period of 2023[26] Guarantees and Commitments - The company provided a guarantee of 10 million yuan for its subsidiary, with a guarantee balance of 10 million yuan, which is 50% of the net assets[14][15] - The company provided a total of 90 million yuan in guarantees for loans, with a remaining balance of 53.8 million yuan as of September 30, 2024[16] - The company has signed a maximum guarantee contract with China Construction Bank for 90 million yuan, with a cumulative loan balance of 53.8 million yuan as of September 30, 2024[18] Other Financial Metrics - Non-recurring gains and losses totaled CNY 4,986,253.46 after tax, contributing positively to the overall financial results despite operational losses[6] - The company’s weighted average return on equity based on net profit attributable to shareholders was -5.65%, down from -2.29% in the previous year[3] - Basic and diluted earnings per share for the first nine months of 2024 were both -¥0.18, compared to -¥0.08 in the same period of 2023[28]
辰光医疗(430300) - 2024 Q3 - 季度财报